CareDx reports preliminary Q4 revenue growth of 25% year-over-year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026 7:05 AM ESTExpects Fourth Quarter Revenue Growth of Approximately 25% Year-Over-Year
Expects Full Year 2025 Revenue of Approximately $380 Million
BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2025.
Preliminary Fourth Quarter 2025 Financial Results
Revenue of approximately $108 million, an increase of 25% year-over-year Testing services revenue of approximately $78... More